Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Gentian Diagnostics AS's annualized ROCE % for the quarter that ended in Jun. 2026 was 14.90%.
Gentian Diagnostics AS (OSTO:GENTOo) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS (OSTO:GENTOO) has a ROCE % of 14.90% as of Jun. 2026.
Is Gentian Diagnostics AS's ROCE % too high?
Gentian Diagnostics AS's current ROCE % is 14.90%. The Medical Devices & Instruments industry median ROCE % is 2.93. Gentian Diagnostics AS's value of 14.90% is 408.5% above this industry median. Overall, Gentian Diagnostics AS has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's ROCE % compare to ABT and SYK?
Gentian Diagnostics AS's ROCE % of 14.90% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.93. Gentian Diagnostics AS's value of 14.90% is 408.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.93, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gentian Diagnostics AS's current ROCE % of 14.90% is 408.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gentian Diagnostics AS's current ROCE % is 14.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSTO:GENTOO) is currently considered Modestly Undervalued. The stock's GF Value™ is kr53.59, compared to a current price of kr40.00 — trading 25.4% below its estimated fair value. The current ROCE % is 14.90% and 408.5% above the Medical Devices & Instruments industry median of 2.93. Gentian Diagnostics AS's overall GF Score™ is 60/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Gentian Diagnostics AS (OSTO:GENTOO), the current ROCE % is 14.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (OSTO:GENTOO) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of kr40.00 is trading 25.4% below its estimated GF Value™ of kr53.59.
GuruFocus considers Gentian Diagnostics AS to be Modestly Undervalued.
Key valuation signals for OSTO:GENTOO:
ROCE %: 14.90%
GF Value™: kr53.59 vs. price of kr40.00 (25.4% below fair value)
Industry Position: 408.5% above the Medical Devices & Instruments median
No single metric tells the full story. See the OSTO:GENTOO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
60GF Score
Get the complete analysis for OSTO:GENTOO
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:GENTOO has been successfully added to your 
